Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrasimod in Pyoderma Gangrenosum
NCT03072953Phase 2Terminated
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jun 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of etrasimod in pyoderma gangrenosum (PG), sponsored by Arena Pharmaceuticals, Inc.. Started Jun 2017; status: terminated.
02
Drugs
etrasimod
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT03072953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03072953.